. Author manuscript; available in PMC: 2020 Dec 1.

Published in final edited form as: Prostate Cancer Prostatic Dis. 2019 Nov 19;23(2):316–323. doi: 10.1038/s41391-019-0188-4

Table 2.

Multivariable analysis including genomic and clinicopathologic features

	HR	LHR	UHR	P-val
Bi-allelic RB1 loss	3.01	1.40	6.46	0.005*
Germline variant HSD3B1	1.85	1.01	3.37	0.045*
Metastases present at ADT initiation	3.21	1.72	5.98	0.0002*
ECOG ≥ 1	1.25	0.70	2.21	0.45
Gleason ≥ 8	0.95	0.55	1.64	0.85
Treatment with enzalutamide / abiraterone	1.00	0.54	1.85	0.995
log(PSA) at biopsy	1.54	1.01	2.35	0.046*